FDA Approves New Narcolepsy Type 1 Treatment for Adults

Why it matters locally: The approval of Orzeyful offers a new treatment option for North Carolinians living with narcolepsy type 1, potentially improving quality of life for those affected by the chronic neurological disorder.

The U.S. Food and Drug Administration (FDA) has approved Orzeyful (oveporexton) tablets for the treatment of narcolepsy type 1 in adults. The decision provides a new medication option for individuals diagnosed with the chronic neurological sleep disorder. Narcolepsy type 1 is characterized by excessive daytime sleepiness and cataplexy, a sudden loss of muscle tone triggered by strong emotions. Individuals with the condition also experience other symptoms, including fragmented nighttime sleep and sleep paralysis. The FDA's approval indicates that Orzeyful can address the range of these symptoms experienced by adult patients. Further details regarding the drug's mechanism of action and clinical trial data were not immediately available from the initial announcement.